Tinzaparin in the Treatment of the Acute Pulmonary Embolism

Inclusion Criteria: * Symptomatic pulmonary embolism patients confirmed by: * High probability ventilation/perfusion lung scan according to the PIOPED criteria * Spiral chest computed tomography, or * Pulmonary arteriography * Aged 18 years or above, of either sex * The patient must provide signed informed consent * Patients will be agreed for receiving ambulatory anticoagulant treatment Exclusion Criteria: * Massive pulmonary embolism * Allergy to heparin, other components of Tinzaparin or acenocoumarol * Previous thrombocytopenia induced by heparin * Thrombocytopenia \< 100000/mm3 * History/signs/symptoms of congenital bleeding disorder * Life expectancy less than 90 days * Unfractioned heparin anticoagulation for more than 36 hours prior enrollment * Inability to participate in the home tinzaparin program * Clinical overt gastrointestinal blood loss due to peptic ulcer, intestinal tumours, oesophagitis or diverticulosis * Hemoglobin lower than 7 g/dL or Creatinin \> 3mg/dL * Cerebral-vascular accident * Cerebral, medullary and ophthalmological surgery